Compound information
- Natural Products
- NACP102502
- Molecular Formula
- C16H21N3O3
- Molecular Weight
- 303.158291532 g/mol
- Structure
-
- IUPAC Name
- (3-acetyl-4,8b-dimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl) N-methylcarbamate
- InChI
- InChI=1S/C16H21N3O3/c1-10(20)19-8-7-16(2)12-9-11(22-15(21)17-3)5-6-13(12)18(4)14(16)19/h5-6,9,14H,7-8H2,1-4H3,(H,17,21)
- InChI Key
- PJHHQGQQTSEDMC-UHFFFAOYSA-N
- SMILES
- O=C(OC1=CC=C2C(=C1)C3(C)CCN(C(=O)C)C3N2C)NC
- CAS
- SuperClass
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- SubClass
- Pyrroloindoles
- Source
- CNP0420944
Warheads
- Carbamate
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 22 | Ring Count | 3 |
| Heteroatom Count | 6 | Rotatable Bond Count | 1 |
| Hydrogen Bond Acceptor Count | 4 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 61.88 Å2 | LogP | 1.38 |
| LogS | -2.12 | LogD | 1.758 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.996 | Pgp substrate | 0.918 |
| HIA | 0.014 | F20 % | 0.792 |
| F30 % | 0.011 | Caco-2 | -5.003 |
| MDCK | -4.755 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.754 | PPB | 87.332 |
| VD | 1.249 | Fu | 0.212 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.003 | CYP1A2 substrate | 0.527 |
| CYP2A6 substrate | 0.818 | CYP2B6 substrate | 0.696 |
| CYP2C19 inhibitor | 0.185 | CYP2C19 substrate | 0.632 |
| CYP2C8 substrate | 0.59 | CYP2C9 inhibitor | 0.068 |
| CYP2C9 substrate | 0.981 | CYP2D6 inhibitor | 0.521 |
| CYP2D6 substrate | 0.805 | CYP2E1 substrate | 0.861 |
| CYP3A4 inhibitor | 0.006 | CYP3A4 substrate | 0.988 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.838 | CL | 7.233 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.001 | Hepatotoxicity | 0.165 |
| Mutagenicity | 0.001 | Rat Oral Acute Toxicity | 0.995 |
| FDAMDD | 0.787 | Skin Sensitization | 0.974 |
| Carcinogenicity | 0.598 | Eye Corrosion | 0.003 |
| Eye Irritation | 0.001 | Respiratory Toxicity | 0.033 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | -0.341 | IGC50 | 2.323 |
| LC50FM | 0.525 | LC50DM | 0.758 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.565 | NR-AR-LBD | 0.234 |
| NR-AhR | 0.314 | NR-Aromatase | 0.045 |
| NR-ER | 0.417 | NR-ER-LBD | 0.367 |
| NR-PPAR-gamma | 0.187 | SR-ARE | 0.53 |
| SR-ATAD5 | 0.498 | SR-HSE | 0.077 |
| SR-MMP | 0.054 | SR-p53 | 0.397 |
Similar covalent drugs
No similar covalent drugs found for this compound.